Preclinical to Clinical Development: Targeting the NLRP3 Inflammasome in Myelodysplastic Syndrome

Time: 8:30 am
day: Conf Day 1

Details:

  • NLRP3 inflammasome is constitutively active in myelodysplastic syndrome (MDS)
  • Novartis is starting clinical trials to assess the impact of anti-inflammatory molecules in low-risk MDS

Speakers: